Cystinosis is a rare genetic disorder that affects the body's ability to transport and process the amino acid cystine. This condition can lead to the accumulation of cystine crystals in various organs, causing significant health issues if left untreated. Fortunately, the field of cystinosis treatment has witnessed remarkable progress in recent years, leading to a growing cystinosis treatment market.
Understanding Cystinosis
Before delving into the cystinosis treatment market, it's essential to comprehend the condition itself. Cystinosis primarily affects children and is categorized into three main forms: nephropathic cystinosis, intermediate cystinosis, and non-nephropathic (ocular) cystinosis. Nephropathic cystinosis is the most severe form and can lead to kidney dysfunction, growth retardation, and other systemic complications if not managed properly.
Treatment Approaches
1. Cysteamine Therapy: Historically, the cornerstone of cystinosis treatment has been cysteamine, which helps to reduce cystine buildup within cells. Oral cysteamine therapy has shown significant efficacy in slowing disease progression, particularly in nephropathic cystinosis.
2. Kidney Transplant: In cases where cystinosis has progressed to end-stage kidney disease, kidney transplantation is a viable option. This procedure can offer improved renal function and overall quality of life.
3. Gene Therapy: Recent advancements in gene therapy have shown promise in treating cystinosis at its root by correcting the underlying genetic mutations. Although still in experimental stages, this approach holds significant potential for the future of cystinosis treatment.
The Cystinosis Treatment Market
The cystinosis treatment market has been expanding as a result of increased awareness, improved diagnostics, and innovative therapies. Key market trends include:
1. Therapeutic Advancements: Research and development efforts have led to the emergence of novel cystinosis therapies, including sustained-release formulations of cysteamine, which reduce dosing frequency and enhance patient compliance.
2. Rare Disease Incentives: Governments and regulatory bodies in various countries have implemented incentives to encourage the development of treatments for rare diseases like cystinosis. This has led to increased investment in research and development within the field.
3. Global Collaboration: International collaboration among researchers, clinicians, and pharmaceutical companies has facilitated the sharing of knowledge and expertise, accelerating progress in cystinosis treatment.
4. Patient-Centric Approaches: Patient advocacy groups play a vital role in advancing cystinosis treatment. Their efforts help raise awareness, provide support to affected individuals and their families, and drive research initiatives.
5. Access to Therapies: While innovative treatments are on the horizon, ensuring equitable access to these therapies remains a challenge. Advocacy for affordable and accessible cystinosis treatments is crucial for patients worldwide.
Conclusion
The cystinosis treatment market has witnessed significant growth in recent years, thanks to advancements in therapeutic approaches and increased global collaboration. While there is still work to be done to improve access to these treatments, the future looks promising for individuals living with cystinosis. Continued research, development, and advocacy efforts are essential to further enhance the lives of those affected by this rare genetic disorder.
Read More….
Batten Disease Treatment Market
Vertebral Compression Fracture Devices Market
Gunshot Injuries Treatment Market
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
The Spirulina Market is expected to grow at a CAGR of 10.3% from 2020-2030, according to a new research report by Next Move Strategy ConsultingSpirulina is a blue green algae with high nutrient content, usually consumed by human & animals.
It is also used as a complementary diet ingredient in aquaculture & poultry feeds owing to the presence of high protein & vitamin content.According to the report, growth in health consciousness among people and the rising demand for dietary supplements are major factors driving the spirulina market growth.
Additionally, high penetration of spirulina in industries such as cosmetics and pharmaceutical owing to the advantageous properties such as anti-aging, anti-wrinkles and othersare bringing changes in market tends.However, low stability & poor sustainability of spirulina derived colours is expected to restrict the market growth.Moreover, growth in research & development activities followed by untapped market opportunities in developing economies are anticipated to provide numerous opportunities to the market players in the coming few years.On the basis of type, spirulina market share is segmented into Arthrospira Platensis and Arthrospira Maxima.
Arthrospira Maxima dominates the global Spirulina market and will be the dominant throughout the forecasted period.On the basis of application, the Spirulina market is categorised into Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others.Food & Beverages segment is likely to develop significantly over the period of time owing to fast growing food & beverage industry.On the basis of drug formulation, the spirulina market is bifurcated into Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent.
Powder segment is expected to account for the major market share & dominate the market growth over the forecast period.North America dominates the spirulina market in terms of market size over the forecast period, owing to rising health consciousness among people.
Hansen Holding A/S, Algenol Biofuels Inc., Dongtai City Spirulina Bio-engineering Co., Ltd., Prolgae, Parry Neutraceuticals, Sensient Technologies Corporation, DDW Inc., Algatec and Naturex S.A.Browse key industry insights from the report, “Spirulina Market Size By Type (ArthrospiraPlatensis and Arthrospira Maxima) By Application (Nutraceuticals, Food & Beverages, Cosmetics, Animal Feed, and Others), By Drug Formulation (Powder, Tablet & Capsule, Liquid, and Granule & Gelling Agent)Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Italy, Russia, China, India, Japan, Australia, Indonesia, Malaysia, South Korea, Brazil, Mexico, South Africa, Saudi Arabia, UAE, Kuwait), Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020–2030” in detail along with the table of contents:Key Insights from the Spirulina Market Report:Asia Pacific is the fastest growing region in Spirulina market owing to the rising demand of spirulina from various industries such as cosmetics, food , healthcare and others and government initiatives to promote local spirulina production.The Food & Beverages segment dominates the market in terms of application and is expected to grow at a significant CAGR to maintain the lead till 2030.Some of the major players in the market are DIC Corporation, Cyanotech Corporation, Chr.
The new report by Expert Market Research titled, ‘Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market Report and Forecast 2021-2026’, gives an in-depth analysis of the global ABSSSI market, assessing the market based on its segments like infection type, route of administration, distribution channel, and major regions like Asia Pacific, Europe, North America, Middle East and Africa and Latin America.
The sample report shall be delivered to you within 24 hours.Request a free sample copy in PDF or view the report summary@https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-market/requestsampleThe key highlights of the report include:Market Overview (2021-2026)Historical Market Size (2020): USD 9.3 BillionForecast CAGR (2021-2026): 7%Forecast Market Size (2026): USD 14 BillionThe growth of global ABSSSI is driven by the rising prevalence of skin infections.
Additionally, the developing antibiotic resistance in pathogenic bacteria, and mutations resulting in the newer strains is expected to drive the demand for the ABSSI Market.
Further the government spending on healthcare and infrastructure will propel the market in the forecast period.Industry Definition and Major SegmentsABSSSI are mild or severe forms infections caused by pathogens like streptococcus pyogenes and Staphylococcus aureus.
These drugs are pathogen specific and may require surgical excision of lesion in extreme cases.Explore the full report with the table of contents@https://www.expertmarketresearch.com/reports/acute-bacterial-skin-and-skin-structure-infections-absssi-treatment-marketThe acute bacterial skin and skin structure infections (ABSSSI) treatment industry can be segmented by infection type:Hospital-acquired ABSSSICommunity-acquired ABSSSIOthersIt may be differentiated on the basis of route of administration:OralParenteralThe industry may be classified on the basis of distribution channel:Hospital PharmacyRetail PharmacyOnlineOthersLatest Global News on Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Treatment Market@https://www.expertmarketresearch.com/pressrelease/global-absssi-treatment-marketOn the basis of regional markets, the industry is divided into:1 North America1.1 United States of America1.2 Canada2 Europe2.1 Germany2.2 United Kingdom2.3 France2.4 Italy2.5 Others3 Asia Pacific3.1 China3.2 Japan3.3 India3.4 ASEAN3.5 Others4 Latin America4.1 Brazil4.2 Argentina4.3 Mexico4.4 Others5 Middle East & Africa5.1 Saudi Arabia5.2 United Arab Emirates5.3 Nigeria5.4 South Africa5.5 OthersMarket TrendsRegionally, North America is the largest shareholder in the global ABSSSI market, due to the presence of a robust healthcare system.
This can be attributed to the rapidly advancing healthcare sector, increasing population, and growing awareness about various skin aliments.Key Market PlayersThe major players in the market are Debiopharm International SA, Melinta Therapeutics, Inc., Paratek Pharmaceuticals, Inc., GlaxoSmithKline plc, and a few others.
